Abstract:Hypertension is an independent risk factor for stroke. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptor-dependent transcription factors. PPAR agonist fenofibrate has been shown to abrogate increased arterial prepro-endothelin-1 (preproET-1) and superoxide levels in deoxycorticosterone acetate (DOCA)-salt hypertension with unknown mechanism(s). We have reported that ET-1 induces endothelial dysfunction in the carotid arteries via NADPH oxidase-derived superoxide in this low renin hypertension model. Therefore, the present study tested the hypothesis that chronic PPAR activation in vivo reduces blood pressure and endothelial dysfunction via impeding cerebrovascular NADPH oxidase/superoxide and augmenting eNOS cofactor tetrahydrobiopterin (BH4) in DOCA-salt rats. DOCA-salt or sham-operated adult male rats were treated with fenofibrate (150 mg/kg/day) for 4 weeks beginning with DOCA-salt regimen. Oxidative stress markers and endothelial function were determined in the carotid arteries afterwards. Average systolic blood pressure was significantly increased in DOCA-salt rats (1868 vs. 1223 mmHg, DOCA vs. sham), which was blunted by fenofibrate (1868 vs. 1396 mmHg, DOCA vs. DOCA+PPAR, all n=11–16, p<0.01). Concomitantly, treatment with fenofibrate significantly reduced arterial NADPH oxidase activity (44.24.2 vs. 21.61.7 nmol/min/mg tissue DOCA vs. DOCA+PPAR), superoxide level (0.620.04 vs. 0.370.04 nmol/min/mg protein), VCAM-1 expression (0.460.07 vs. 0.280.04, VCAM-1/actin ratio, all n=5–10, p<0.05) and serum lipid peroxidation (TBAR 1.920.08 vs. 5.181.9 mol/L, n=10, p<0.01). Furthermore, treatment with fenofibrate significantly augmented arterial BH4 level (1.230.21 vs. 3.210.88 pmol/mg protein, n=7–8, p<0.05) and endogenous eNOS activity (6.000.40 vs. 12.961.61 nmol/mg protein, DOCA vs. DOCA+PPAR, n=8-9, p<0.05), resulting in improved endothelium-dependent NO-mediated relaxation in response to acetylcholine (39.732.98 vs. 78.313.83%, DOCA vs. DOCA+PPAR, n=9–10, p<0.05). These findings indicate that in vivo PPARá activation prevents progression of hypertension and reduces cerebrovascular endothelial dysfunction via impeding arterial NADPH oxidase-derived superoxide and augmenting eNOS essential cofactor BH4 in low renin mineralocorticoid hypertension. (Supported by American Heart Association grants 0130537Z and 0455594Z (to AFC), China Medical Board (CMB) grant 00730 and the National Natural Sciences Foundation of China grants 39940012 and 30271485 (to JSZ).

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

Modulation of LPS-mediated Inflammation by Fenofibrate Via the TRIF-dependent TLR4 Signaling Pathway in Vascular Smooth Muscle Cells.

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

PPARα Agonist Fenofibrate Attenuates TNF-α-induced CD40 Expression in 3T3-L1 Adipocytes Via the SIRT1-dependent Signaling Pathway

Activation of PPAR Alpha by Fenofibrate Inhibits Apoptosis in Vascular Adventitial Fibroblasts Partly Through SIRT1-mediated Deacetylation of FoxO1.

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension.

Fenofibrate Ameliorates Cardiac Hypertrophy by Activation of Peroxisome Proliferator-Activated Receptor-Α Partly Via Preventing P65-Nfκb Binding to NFATc4.

Fenofibrate Enhances the in Vitro Differentiation of Foxp3+ Regulatory T Cells in Mice

Activation of peroxisome proliferator-activated receptor-α prevents glycogen synthase 3β phosphorylation and inhibits cardiac hypertrophy

Fenofibrate Decreases Asymmetric Dimethylarginine Level in Cultured Endothelial Cells by Inhibiting NF-κB Activity

PPAR γ agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway

In vivo PPAR|[alpha]| activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting tetrahydrobiopterin in mineralocorticoid hypertension

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Effects of Fenofibrate on Tumor Necrosis Factor-Α Expression Induced by Lipopolysaccharide in Neonatal Rat Cardiac Myocytes

PPARγ Enhances IFNγ-mediated Transcription and Rescues the TGFβ Antagonism by Stimulating CIITA in Vascular Smooth Muscle Cells

Fenofibrate Inhibited the Differentiation of T Helper 17 Cells in Vitro

PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

C-reactive Protein-Induced Expression of CD40-CD40L and the Effect of Lovastatin and Fenofibrate on It in Human Vascular Endothelial Cells.